MARKET INTRODUCTION
Erythropoietin (EPO) is produced by the kidney and used to make red blood cells. Erythropoetin-stimulating agents are used often for people with long-term kidney disease and anemia.
MARKET DYNAMICS
Factors driving the market growth includes, rising burden of anemia, anemia induced due to cancer, end stage renal disease and HIV treatment. According to the World Health Organization (WHO), in 2013, it was projected that pregnant women (38%), non-pregnant women (29%), children (43%), and women of reproductive age (29%) suffer from anemia, resultant to 496 million non-pregnant women, 273 million children, and 32 million pregnant women, globally. However, adverse side effects such as, high blood pressure, swelling, and fever may impede the market growth.
MARKET SCOPE
The "Global Erythropoietin Stimulating Agents Market analysis to 2028" is a specialized and in-depth study of the pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of Erythropoietin Stimulating Agents Market with detailed market segmentation by type, application, and geography. The Global Erythropoietin Stimulating Agents Market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading Erythropoietin Stimulating Agents Market players and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The Global Erythropoietin Stimulating Agents Market is segmented on the basis of type, application. On the basis of type, market can be classified as epoetin alfa, epoetin beta, darbepoetin alfa, and other types On the basis of application, the market is segmented into cancer, renal disorders, anti-retroviral treatment, neural diseases, and other applications.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global Erythropoietin Stimulating Agents Market based on various segments. It also provides market size and forecast estimates from year 2020 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Erythropoietin Stimulating Agents Market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting Erythropoietin Stimulating Agents Market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trends. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Erythropoietin Stimulating Agents Market in these regions.
MARKET PLAYERS
The report covers key developments in the Erythropoietin Stimulating Agents Market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from Erythropoietin Stimulating Agents Market are anticipated to lucrative growth opportunities in the future with the rising demand for Erythropoietin Stimulating Agents Market in the global market. Below mentioned is the list of few companies engaged in the Erythropoietin Stimulating Agents Market.
The report also includes the profiles of key Erythropoietin Stimulating Agents Market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
- Amgen Inc.
- BioSidus
- Biocon Limited
- Celltrion Inc.
- F. Hoffmann-La Roche Ltd
- Intas Pharmaceuticals Ltd
- Johnson and Johnson
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd
- Thermo Fisher Scientific
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.